A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (NCT04562870)
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.
Who can join: Review the eligibility criteria below.
Location: The Oncology Institute of Hope and Innovation — Pasadena, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- The Oncology Institute of Hope and Innovation — Pasadena, California
- Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Illinois Cancer Specialist — Niles, Illinois
- Texas Oncology - Northeast Texas — Tyler, Texas
- Peking Union Medical College Hospital — Beijing, Beijing Municipality
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei
- Affiliated Hospital of Nantong University — Nantong, Jiangsu
- The Second Affiliated Hospital of Soochow University — Suzhou, Jiangsu
- Suzhou University -The First Affiliated Hospital — Suzhou, Jiangsu
- The First Hospital of Jilin University — Changchun, Jilin
- Sir Run Run Shaw Hospital - Zhejiang University School of Medicine — Hangzhou, Zhejiang
- Institut de Cancéro-Hématologie — Brest, Brittany Region
- Centre Hospitalier Universitaire d'Angers (CHU Angers) — Angers,
- University General Hospital "ATTIKON" — Athens, Attica
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS — Meldola, Forlì-Cesena
- Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica — Florence,
- Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti — Latina,
- University of Perugia Department of Medicine Hematology Section — Perugia,
- Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi — Varese,
- Pratia Onkologia Katowice — Katowice,
- Hospital Universitario 12 de Octubre — Madrid, Madrid
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.